Inhibition of Ras attenuates the course of experimental autoimmune neuritis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Experimental autoimmune neuritis (EAN) is an animal model for inflammatory demyelinating polyneuropathies.
• Ras signaling pathways are implicated in inflammatory and immune responses.

Purpose of the Study:

• To investigate the therapeutic potential of the Ras inhibitor farnesylthiosalicylate (FTS) in a rat model of EAN.
• To determine the effects of FTS on clinical outcomes, including disability and recovery.

Main Methods:

• Lewis rats were immunized to induce EAN.
• FTS (5 mg/kg) or saline was administered intraperitoneally twice daily, either from disease onset (day 0) or during the recovery phase (day 10).
• Clinical scores, rotarod performance, and nerve conduction were assessed. An inactive analogue, geranylthiosalicylate, served as a control.

Main Results:

• Treatment with FTS from day 0 significantly attenuated peak clinical scores compared to controls.
• Treatment with FTS from day 10 significantly reduced peak disability and improved recovery.
• Functional recovery was confirmed by rotarod and nerve conduction studies.
• The inactive analogue geranylthiosalicylate showed no clinical effect.

Conclusions:

• Inhibition of Ras signaling with FTS demonstrates therapeutic potential in EAN.
• FTS treatment, particularly when initiated during the recovery phase, can ameliorate clinical signs and improve functional outcomes in inflammatory neuropathies.
• Targeting Ras pathways represents a promising strategy for treating inflammatory neuropathies.